America has just slapped a 12.5% tariff on about one third of Singapore’s domestic exports to the US, off the back of a forced labour probe that our own trade ministry rejects. In this episode I walk Angela through what actually sits inside that tariff and, more importantly, what does not, from exempted semiconductors and pharmaceuticals to banks, REITs, and telcos that earn from lending, rent, and subscriptions instead of US bound goods. We strip the headline down to the wiring that matters at Bedok kopitiam level, asking whether this measure genuinely touches your CPF, SRS, and dividend portfolio or just makes for loud news. I also bring us back to the same forensic questions that always matter more than any single tariff, what your yield looks like versus the 4.7% hurdle, how clean the balance sheet is, and where the income is really coming from.
Key takeaways:
Why a 12.5% tariff on one third of exports leaves most CPF and SRS income untouched
Which goods are exempted, including semiconductors, pharmaceuticals, and key electronics the economy depends on
Why banks, REITs, and telcos sit outside this mechanism because they sell services, not tariffed goods
How to sanity check each stock, by tracing whether its income relies on US bound exports or local lending and rent
Why your 4.7% yield hurdle and gearing limits still matter more than any single Washington headline
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
